# ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

Study · id `cardio:ct-nct05021835` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05021835](<https://clinicaltrials.gov/study/NCT05021835>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05021835

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6385 participants.

## Technical summary

Registry record NCT05021835. Randomized; quadruple masking; primary purpose treatment. Start 2021-08-30 (actual); primary completion 2026-06-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 6385 participants (enrolled count; ClinicalTrials.gov record NCT05021835, source copy `cardio:ctgov-nct05021835-2026-09-28`, retrieved 2026-11-18)
- Started: 2021-08-30 (actual) (ClinicalTrials.gov record NCT05021835, source copy `cardio:ctgov-nct05021835-2026-09-28`, retrieved 2026-11-18)
- Primary completion: 2026-06-09 (actual) (ClinicalTrials.gov record NCT05021835, source copy `cardio:ctgov-nct05021835-2026-09-28`, retrieved 2026-11-18)
- Completion: 2026-06-09 (actual) (ClinicalTrials.gov record NCT05021835, source copy `cardio:ctgov-nct05021835-2026-09-28`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; China; Croatia; Czechia; Denmark; Germany; Greece; Hungary; India; Israel; Italy; Japan; Latvia; Lithuania; Malaysia; Mexico; Netherlands; Poland; Portugal; Romania; Russia; Serbia; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye; Ukraine; United Kingdom (ClinicalTrials.gov record NCT05021835, source copy `cardio:ctgov-nct05021835-2026-09-28`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05021835-2026-09-28`, retrieved 2026-11-18)

## The registry's words

- Brief title: ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
- Acronym: ZEUS
- Condition: Cardiovascular Risk
- Condition: Chronic Kidney Disease
- Condition: Inflammation
- Intervention (Drug): Ziltivekimab B
- Intervention (Drug): Ziltivekimab C
- Intervention (Drug): Placebo (Ziltivekimab B)
- Intervention (Drug): Placebo (Ziltivekimab C)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 0cea02727d86867e78bef0abc899f08aa06f3eda9fb0c36db95ac2ab51c77316
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
